ibandronic acid has been researched along with zoledronic acid in 140 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.43) | 18.2507 |
| 2000's | 64 (45.71) | 29.6817 |
| 2010's | 55 (39.29) | 24.3611 |
| 2020's | 19 (13.57) | 2.80 |
| Authors | Studies |
|---|---|
| Martin, MB; Oldfield, E; Szabo, CM | 1 |
| Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L | 1 |
| Araujo, FG; Chan, JM; Ling, Y; Moreno, SN; Odeh, S; Oldfield, E; Sahota, G | 1 |
| Hall, P; Hudock, MP; Leon, A; Liu, L; Morita, CT; Oldfield, E; Puan, KJ; Studer, D; Yang, Y; Yin, F | 1 |
| Bauss, F; Haiker, M; Künkele, KP; Lühe, A; Pfister, T; Schad, K; Suter, L; Zihlmann, C | 1 |
| Barnett, BL; Dunford, JE; Ebetino, FH; Kavanagh, KL; Kwaasi, AA; Oppermann, U; Rogers, MJ; Russell, RG | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Axelson, J; Cao, R; Chang, SC; Chang, TH; Guo, RT; Hudock, MP; K-M Chen, C; Ko, TP; Kumar, A; Liang, PH; No, JH; Oldfield, E; Song, Y; Wang, AH; Zhang, Y | 1 |
| Cass, LM; Chang, TK; Mukkamala, D; No, JH; Oldfield, E | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Almeida Paz, FA; Barbosa, JS; Braga, SS | 1 |
| Ziegler, J | 1 |
| Enomoto, K | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
| Body, JJ | 2 |
| Body, JJ; Fromigue, O; Lagneaux, L | 1 |
| Body, JJ; Fromigué, O | 1 |
| Biskobing, DM; Downs, R; Novy, AM | 1 |
| Boissier, S; Cabon, F; Clézardin, P; Colombel, M; Filleur, S; Fournier, P; Guglielmi, J | 1 |
| Berenson, JR | 1 |
| Heidenreich, A | 1 |
| Atzpodien, E; Bauss, F; Pfister, T | 1 |
| Adami, S; Crepaldi, G; Filipponi, P; Sartori, L | 1 |
| Hirschberg, R | 1 |
| Berenson, J; Hirschberg, R | 1 |
| Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U | 1 |
| Boos, J; Lanvers-Kaminsky, C; Vorotnjak, M | 1 |
| Harvey, HA | 1 |
| Khuri, F; Saba, N | 1 |
| Chapurlat, RD | 1 |
| Wallace, DJ | 1 |
| Coleman, RE | 1 |
| Balla, J | 1 |
| Lugassy, G | 1 |
| Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP | 2 |
| Kuehn, BM | 1 |
| Lipton, A | 1 |
| Gordon, DH | 1 |
| Fietkau, R; Gundlach, KK; Lenz, JH; Mueller, PC; Schmidt, W; Steiner-Krammer, B | 1 |
| Geusens, P; Reid, D | 1 |
| Atzpodien, E; Bauss, F; Bohrmann, B; Pfister, T | 1 |
| Franke, HR; Verdijk, R; Vermes, I; Wolbers, F | 1 |
| Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B | 1 |
| Botsis, D; Christodoulakos, G; Lambrinoudaki, I | 1 |
| Armamento-Villareal, R; Civitelli, R; Napoli, N | 1 |
| Bergström, B; Body, JJ; Garnero, P; Lichinitser, M; Tjulandin, S | 1 |
| Maricic, M | 1 |
| Binder, M; Dieterle, F; Ross, A; Schlotterbeck, G; Senn, H; Suter, L | 1 |
| Body, JJ; Chaboteaux, C; Duvillier, H; Journé, F; Kheddoumi, N; Laurent, G | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R | 1 |
| McKeage, K; Plosker, GL | 1 |
| Baldini, E; Barni, S; Berto, P; Cortesi, E; Dauria, G; Schivazappa, C | 1 |
| Márton, I; Redl, P; Udvardy, E | 1 |
| Joensuu, TK | 1 |
| Hagino, H; Hashimoto, J; Katagiri, H; Okano, T | 1 |
| Hochberg, MC | 1 |
| Colombel, M | 1 |
| Kalogeropoulou, C; Kardamakis, D; Vassiliou, V | 1 |
| Bartl, R | 1 |
| Antràs, L; Diel, IJ; Duh, MS; Green, J; Köppler, H; Neary, M; Smith, M; Weide, R; Wintfeld, N | 1 |
| Okazaki, R | 1 |
| Bao, C; Gao, Y; Hu, J; Liu, X; Zou, S | 1 |
| Bilezikian, JP | 1 |
| Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K | 1 |
| Al-Nawas, B; Brüllmann, D; Gauss, L; Kämmerer, P; Klein, MO; Pabst, A; Walter, C; Ziebart, T | 1 |
| Grieve, RJ; Hamilton, E; Hickish, T; Houston, S; Percival, F | 1 |
| Henry, C; Jahnke, W | 1 |
| Lindor, KD; Petz, JL; Silveira, MG; Treeprasertsuk, S | 1 |
| Cole, R | 1 |
| Al-Nawas, B; Klein, M; Pabst, A; Walter, C; Ziebart, T | 1 |
| Al-Nawas, B; Koch, FP; Merkel, C; Smeets, R; Walter, C; Ziebart, T | 1 |
| Bauss, F; Drosse, I; Ehrenfeld, M; Opelz, C; Otto, S; Pautke, C; Schieker, M; Schwager, J; Westphal, I | 1 |
| Al-Nawas, B; Koch, FP; Merkel, C; Smeets, R; Wagner, W; Walter, C; Ziebart, T | 1 |
| Abrams, J; Bhargaval, A; Graff, JJ; Nahleh, Z; Nirmal, K | 1 |
| Pazianas, M | 1 |
| Al-Nawas, B; Koch, FP; Pabst, AM; Taylor, KY; Walter, C; Ziebart, T | 1 |
| Bargagli, G; Conca, R; Cozzolino, A; Fiaschi, AI; Francini, E; Francini, F; Gotti, G; Martellucci, I; Miano, ST; Migali, C; Pascucci, A; Petrioli, R | 1 |
| Carter, D; Churchill, W; Clapp, M; Reddy, P; Slovik, D; Yeh, Y | 1 |
| Bhattacharyya, I; Bowers, LM; Cohen, DM; Fitzpatrick, SG; Green, JG; Hinkson, DW; Neuman, AN; Stavropoulos, MF | 1 |
| Bissinger, O; Ehrenfeld, M; Kolk, A; Mast, G; Mücke, T; Otto, S; Pautke, C; Schreyer, C; Stürzenbaum, SR; Wolff, KD | 1 |
| Curtis, JR; Delzell, E; Matthews, R; Saag, KG; Yun, H | 1 |
| Grätz, KW; Jacobsen, C; Metzler, P; Obwegeser, J; Rössle, M; Zemann, W | 1 |
| Kraenzlin, CA; Kraenzlin, ME; Lardelli, P; Meier, C; Sieber, P | 1 |
| Achel, DG; Alcaraz, M; Alcaraz-Saura, M; Olivares, A | 1 |
| Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J | 1 |
| Barrett-Lee, P; Fenlon, D; Griffiths, G; Harrop, E; Hood, K; Morris, J; Murray, N; Nelson, A; Sampson, C; Wheatley, D | 1 |
| Brown, J; Fullarton, JR; Palmieri, C | 1 |
| Agodoa, I; Kruse, M; Orwoll, E; Parthan, A; Silverman, S | 1 |
| Alegre, A; Bailén, A; Giraldo, P; Gironella, M | 1 |
| Costa, L | 1 |
| Abraham, J; Barrett-Lee, P; Casbard, A; Coleman, R; Grieve, R; Griffiths, G; Hood, K; Murray, N; Simmonds, P; Timmins, H; Wheatley, D | 1 |
| Caffarelli, C; Franci, BM; Gonnelli, S; Lucani, B; Nuti, R; Pondrelli, C; Tanzilli, L | 1 |
| Hagelauer, N; Pabst, AM; Ulbrich, H; Walter, C; Ziebart, T | 1 |
| Al-Rifaiy, MQ; Almas, K; Javed, F; Vohra, F | 1 |
| Felsenberg, D; Gabbert, TI; Hoffmeister, B | 1 |
| Reid, IR | 1 |
| Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S | 1 |
| Criscitiello, C; Curigliano, G; De Laurentiis, M; De Placido, S; Esposito, A; Gelao, L; Goldhirsch, A; Santangelo, M; Viale, G | 1 |
| Curtis, D; Lu, Y; Qiao, D; Wang, Z; Wen, X; Yao, Y; Zhao, H | 1 |
| Bohlmann, MK; Luedders, DW; Rody, A; Steinhoff, J; Thill, M | 1 |
| Jacobs, C; Krüger, M; Pabst, AM; Sagheb, K; Walter, C; Ziebart, T | 1 |
| Bergner, R; Gretz, N; Kränzlin, B; Pohlmeyer-Esch, G; Siegrist, B | 1 |
| Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR | 1 |
| Adami, S; Gatti, D; Rossini, M; Viapiana, O | 1 |
| Galiti, D; Galitis, E; Karampeazis, A; Labropoulos, S; Migliorati, C; Nicolatou-Galitis, O; Razis, E; Sgouros, J; Tsimpidakis, A | 1 |
| Ataoğlu, B; Berkay, AF; Eren, TK; Kaptan, AY; Yapar, AE | 1 |
| Mészaros, Á; Veszelyné Kotán, E | 2 |
| Campbell, F; Davis, S; Gittoes, N; Goka, E; Martyn-St James, M; Rawdin, A; Sadler, S; Sanderson, J; Selby, P; Stevens, J; Stevenson, M; Strong, M; Wong, R | 1 |
| Harris, ST; Insinga, R; Lewiecki, EM; Modi, A; Sajjan, S; Weaver, J | 1 |
| Barrett-Lee, P; Casbard, A; Farewell, D; Gillespie, D; Hawthorne, AB; Hood, K; Hurt, C; Murray, N; Probert, C; Stenson, R | 1 |
| Jiang, LA; Leder, BZ; Lee, H; Tsai, JN | 1 |
| Buffat, H; Curkovic, I; Lippuner, K; Popp, AW; Popp, PF; Senn, C; Senn, R | 1 |
| Ermer, MA; Kottmann, SC; Otten, JE; Pelz, K; Poxleitner, P; Wittmer, A | 1 |
| Al-Nawas, B; Jung, J; Kwon, YD; Pabst, AM; Park, JS; Righesso, L; Walter, C | 1 |
| Han, J; Han, L; Liu, X; Wang, T; Zhang, H; Zhang, J; Zhang, L | 1 |
| Appelt, KA; Meier, C; Müller, F; Suhm, N | 1 |
| Abrams, JS; Barlow, WE; Chew, HK; Clemons, M; Dakhil, SR; Dammann, KZ; Dees, EC; Elias, AD; Falkson, CI; Gralow, JR; Hayes, DF; Hershman, DL; Hortobagyi, GN; Ingle, JN; Lew, DL; Livingston, RB; M'iao, JL; Margolis, JH; Messino, MJ; Paterson, AHG; Schubert, MM; Stopeck, AT; Van Poznak, CH | 1 |
| Costela-Ruiz, VJ; García-Martínez, O; Illescas-Montes, R; Manzano-Moreno, FJ; Melguizo-Rodriguez, L; Ramos-Torrecillas, J; Ruiz, C | 1 |
| Chen, TS; Hsu, YC; Kao, FC; Liu, PH; Tu, YK | 1 |
| Abou Zahr, Z; Ji, Y; Mahmood, SB; Peng, Y | 1 |
| Abbas, U; Axelrod, D; Bhasin, R; Bozzo, A; Deng, J; Deodat, M; Ghert, M; Masrouha, K; Sanger, S; Turcotte, R; Wariach, S; Wilson, D | 1 |
| Halling, F; Lux, C; Otto, M; Schlittenbauer, T; Ziebart, T | 1 |
| Feng, D; Ke, L; Liu, J; Luo, F; Mori, T; Wan, Y; You, R; Yu, G; Zhang, Y | 1 |
| Chang, YF; Hsu, JC; Hsu, YH; Li, CC; Liang, FW; Ou, HT; Peng, ZY; Wu, CH | 1 |
| Baim, S; Bedrose, S; Casagrande, A; Go, MT; Goel, M; Hanna, M; Husni, H; Li, D; Mahrous, P; Morkos, M | 1 |
| Chen, CH; Chen, WJ; Chen, YM; Chien, LN; Ku, CK; Li, CY; Lin, SY | 1 |
| Bartsch, R; Borchert, J; Hadji, P; Kossack, N; O'Kelly, J; Pignot, M | 1 |
| Aoki, K; Nakamura, M; Saito, N; Ueda, K; Yamamoto, Y; Yudasaka, M; Zhang, M | 1 |
| Huang, J; Li, P; Li, Y; Wu, X | 1 |
| McConnell, M; Shieh, A | 1 |
| Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T | 1 |
| Bonel, H; Everts-Graber, J; Gahl, B; Häuselmann, H; Lehmann, D; Lehmann, T; Reichenbach, S; Studer, U; Ziswiler, HR | 1 |
| Chen, LH; Ma, WJ; Wang, WY; You, RX | 1 |
| Bastounis, A; Bishop, S; Corp, N; Gittoes, N; Griffin, J; Langley, T; Leonardi-Bee, J; Narayanasamy, MJ; Paskins, Z; Sahota, O | 1 |
44 review(s) available for ibandronic acid and zoledronic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans | 2021 |
[New drugs in metastatic breast cancer--1997].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Diphosphonates; Drug Resistance, Multiple; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Tamoxifen; Taxoids; Triazoles; Zoledronic Acid | 1997 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Current and future directions in medical therapy: hypercalcemia.
Topics: Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid | 2000 |
Novel therapeutic options for osteoporosis.
Topics: Animals; Controlled Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Evidence-Based Medicine; Fractures, Spontaneous; Glycoproteins; Humans; Ibandronic Acid; Imidazoles; Norpregnenes; Osteoporosis; Osteoprotegerin; Piperidines; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Selective Estrogen Receptor Modulators; Thiophenes; Zoledronic Acid | 2002 |
Treatment of hypercalcemia of malignancy with bisphosphonates.
Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid | 2002 |
Bisphosphonates in the management of metastatic prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Male; Pain; Palliative Care; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2003 |
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.
Topics: Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Zoledronic Acid | 2003 |
Safety and convenience of a 15-minute infusion of zoledronic acid.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2004 |
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Pamidronate; Postmenopause; Triazoles; Zoledronic Acid | 2004 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clodronic Acid; Diphosphonates; Etidronic Acid; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Imidazoles; Lung Neoplasms; Pamidronate; Positron-Emission Tomography; Predictive Value of Tests; Therapeutic Equivalency; Zoledronic Acid | 2005 |
Rapid prevention of vertebral fractures associated with osteoporosis.
Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogens; Female; Glucocorticoids; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risk Factors; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2005 |
Bisphosphonates in breast cancer.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Staging; Pamidronate; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2005 |
New therapeutic agents for the treatment of bone diseases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Newer drug treatments: their effects on fracture prevention.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Denosumab; Diphosphonates; Fractures, Bone; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Organometallic Compounds; Osteoporosis; Osteoprotegerin; Parathyroid Hormone; RANK Ligand; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thiophenes; Zoledronic Acid | 2005 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Osteonecrosis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2006 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2006 |
New and emerging treatments for osteoporosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Drug Administration Routes; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Patient Compliance; RANK Ligand; Zoledronic Acid | 2007 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid | 2008 |
[Osteonecrosis of the jaw developing during bisphosphonate treatment].
Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Mandible; Mandibular Diseases; Oral Hygiene; Oral Surgical Procedures; Osteonecrosis; Patient Care Team; Referral and Consultation; Zoledronic Acid | 2008 |
[Daily practice using the guidelines for prevention and treatment of osteoporosis. Evolution of bisphosphonate therapy. Intravenous injection].
Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Injections, Intravenous; Osteoporosis; Zoledronic Acid | 2008 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid | 2008 |
[Update on treatment of postmenopausal osteoporosis].
Topics: Bone Resorption; Calcium; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Zoledronic Acid | 2008 |
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Patient Compliance; Risedronic Acid; Zoledronic Acid | 2009 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2009 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Indoles; Jaw Diseases; Macrophages; Magnetic Resonance Imaging; Mevalonic Acid; Monocytes; Mouth Mucosa; Osteoclasts; Osteomyelitis; Osteonecrosis; Positron-Emission Tomography; Pyrroles; Radiography, Panoramic; RANK Ligand; Risedronic Acid; Risk Factors; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2011 |
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Neoplasm Metastasis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2013 |
Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review.
Topics: Antineoplastic Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Ibandronic Acid; Imidazoles; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2014 |
Efficacy of systemic bisphosphonate delivery on osseointegration of implants under osteoporotic conditions: lessons from animal studies.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Dental Implantation, Endosseous; Dental Implants; Dental Restoration Failure; Diphosphonates; Female; Ibandronic Acid; Imidazoles; Osseointegration; Osteoporosis; Ovariectomy; Surface Properties; Zoledronic Acid | 2014 |
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Clodronic Acid; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Immune System; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Treatment Outcome; Zoledronic Acid | 2015 |
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2015 |
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Hydroxycholecalciferols; Ibandronic Acid; Imidazoles; Lumbar Vertebrae; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid | 2015 |
The use of bisphosphonates in women: when to use and when to stop.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors; Time Factors; Zoledronic Acid | 2015 |
Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review.
Topics: Aged; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Fatal Outcome; Female; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Neoplasms; Periodontal Diseases; Radiography, Panoramic; Retrospective Studies; Tooth Extraction; Zoledronic Acid | 2015 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid | 2016 |
A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Topics: Alendronate; Bone Density Conservation Agents; Cost of Illness; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Models, Econometric; Osteoporotic Fractures; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Social Work; State Medicine; United Kingdom; Zoledronic Acid | 2016 |
Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Ibandronic Acid; Lung Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2021 |
Reduced All-Cause Mortality With Bisphosphonates Among Post-Fracture Osteoporosis Patients: A Nationwide Study and Systematic Review.
Topics: Diphosphonates; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Risedronic Acid; Zoledronic Acid | 2022 |
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Male; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Spinal Fractures; Zoledronic Acid | 2022 |
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Polypharmacy; Risedronic Acid; Teriparatide; Zoledronic Acid | 2022 |
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Male; Neoplasms; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2023 |
Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials.
Topics: Denosumab; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures; Teriparatide; Zoledronic Acid | 2023 |
10 trial(s) available for ibandronic acid and zoledronic acid
| Article | Year |
|---|---|
S0307. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Predictive Value of Tests; Survival Rate; Zoledronic Acid | 2005 |
Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteocalcin; Peptide Fragments; Peptides; Procollagen; Zoledronic Acid | 2007 |
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Peptides; Treatment Outcome; Zoledronic Acid | 2011 |
QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Comprehension; Diphosphonates; England; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pain Measurement; Patient Preference; Patient Satisfaction; Patients; Qualitative Research; Quality of Life; Time Factors; Treatment Outcome; Wales; Zoledronic Acid | 2013 |
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Zoledronic Acid | 2014 |
Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Carotid Intima-Media Thickness; Diphosphonates; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Ibandronic Acid; Imidazoles; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Zoledronic Acid | 2014 |
Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases.
Topics: Acute Disease; Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Kidney; Middle Aged; Prospective Studies; Zoledronic Acid | 2015 |
Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Teriparatide; Zoledronic Acid | 2017 |
Comparison of clinical effect in treatment of bone tumor between zoledronic acid needle and ibandronate needle.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Child; Female; Humans; Ibandronic Acid; Injections; Male; Middle Aged; Pain Measurement; Quality of Life; Young Adult; Zoledronic Acid | 2018 |
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
86 other study(ies) available for ibandronic acid and zoledronic acid
| Article | Year |
|---|---|
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats | 2002 |
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques; Kidney; Mice; Pamidronate; Parathyroidectomy; Rats; Skull; Structure-Activity Relationship; Thyroidectomy; Zoledronic Acid | 2002 |
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Topics: Aldose-Ketose Isomerases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Cell Line; Diphosphonates; Fosfomycin; Geranyltranstransferase; Humans; Mice; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Quantitative Structure-Activity Relationship; Toxoplasma; Toxoplasmosis | 2005 |
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
Topics: Anti-Bacterial Agents; Cluster Analysis; Diphosphonates; Drug Synergism; Escherichia coli K12; Fosfomycin; Gene Expression; Geranyltranstransferase; Models, Molecular; Oligonucleotide Array Sequence Analysis; Quantitative Structure-Activity Relationship; Terpenes | 2006 |
Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety.
Topics: Animals; Bone Density Conservation Agents; Cell Line; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Geranyltranstransferase; Humans; Ibandronic Acid; Imidazoles; Inhibitory Concentration 50; Kidney; Male; Pamidronate; Rats; Rats, Sprague-Dawley; RNA, Messenger; Zoledronic Acid | 2008 |
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
Topics: Binding Sites; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Models, Molecular; Molecular Structure; Nitrogen; Stereoisomerism; Structure-Activity Relationship; Time Factors | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Diphosphonates; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Farnesyltranstransferase; Humans; K562 Cells; Magnetic Resonance Spectroscopy; Models, Molecular; Quantitative Structure-Activity Relationship | 2008 |
Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data.
Topics: Animals; Anti-Bacterial Agents; Antiviral Agents; Cell Line, Tumor; Dictyostelium; Diphosphonates; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Leishmania donovani; Models, Chemical; Plasmodium vivax; Predictive Value of Tests | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Research on bone metastases quickens its pace.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Neoplasm Proteins; Palliative Care; Parathyroid Hormone-Related Protein; Proteins; Zoledronic Acid | 1997 |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |
Bisphosphonates induce breast cancer cell death in vitro.
Topics: Amino Acid Chloromethyl Ketones; Annexins; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase Inhibitors; Caspases; Cell Death; Cell Nucleus; Clodronic Acid; Cysteine Proteinase Inhibitors; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Ibandronic Acid; Imidazoles; Kinetics; Pamidronate; Tumor Cells, Cultured; Zoledronic Acid | 2000 |
Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts.
Topics: Adult; Aged; Alkaline Phosphatase; Cell Differentiation; Cell Division; Cell Survival; Cells, Cultured; Clodronic Acid; Collagen Type I; Culture Media; Culture Media, Serum-Free; Diphosphonates; Fetal Blood; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoblasts; Pamidronate; Zoledronic Acid | 2002 |
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
Topics: Angiogenesis Inhibitors; Animals; Bone and Bones; Cell Division; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelium, Vascular; Epithelial Cells; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Neovascularization, Physiologic; Orchiectomy; Osteitis Deformans; Prostate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Testosterone; Tissue Distribution; Zoledronic Acid | 2002 |
The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats.
Topics: Acetylglucosamine; Animals; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Female; Glutathione Transferase; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Kidney Diseases; L-Lactate Dehydrogenase; Rats; Rats, Wistar; Urea; Zoledronic Acid | 2003 |
Nephrotoxicity of third-generation, intravenous bisphosphonates.
Topics: Animals; Diphosphonates; Ibandronic Acid; Imidazoles; Injections, Intravenous; Kidney Diseases; Kidney Tubules, Proximal; Rats; Zoledronic Acid | 2004 |
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid | 2004 |
In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Topics: Alendronate; Apoptosis; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Diphosphonates; Drug Screening Assays, Antitumor; Germany; Humans; Ibandronic Acid; Imidazoles; Neuroblastoma; Pamidronate; Time Factors; Zoledronic Acid | 2004 |
Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2005 |
The issue of renal safety of zoledronic acid from a nephrologist's point of view.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2005 |
"Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Time Factors; Zoledronic Acid | 2005 |
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Metastasis; Pamidronate; Quality of Life; State Medicine; United Kingdom; Zoledronic Acid | 2005 |
Longer-lasting osteoporosis drugs sought.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide; Zoledronic Acid | 2005 |
Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Pamidronate; Quality-Adjusted Life Years; United Kingdom; Zoledronic Acid | 2005 |
Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Mandibular Diseases; Maxillary Diseases; Multiple Myeloma; Osteomyelitis; Osteonecrosis; Zoledronic Acid | 2005 |
Acute renal effects of intravenous bisphosphonates in the rat.
Topics: Animals; Body Weight; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Female; Ibandronic Acid; Imidazoles; Injections, Intravenous; Kidney; Rats; Rats, Inbred Strains; Zoledronic Acid | 2005 |
Differential effects of bisphosphonates on breast cancer cell lines.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid | 2007 |
Use of intravenous bisphosphonates in osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Patient Compliance; Zoledronic Acid | 2007 |
Application of metabonomics in a comparative profiling study reveals N-acetylfelinine excretion as a biomarker for inhibition of the farnesyl pathway by bisphosphonates.
Topics: Animals; Biomarkers; Creatine; Cysteine; Diphosphonates; Geranyltranstransferase; Glucose; Ibandronic Acid; Imidazoles; Molecular Structure; Prenylation; Rats; Signal Transduction; Taurine; Zoledronic Acid | 2007 |
Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bone and Bones; Breast Neoplasms; Calcium; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Synergism; Female; Humans; Ibandronic Acid; Imidazoles; Zoledronic Acid | 2008 |
Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171).
Topics: Administration, Oral; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Osteocalcin; Peptides; Procollagen; Prognosis; Sensitivity and Specificity; Zoledronic Acid | 2008 |
[Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Pamidronate; Zoledronic Acid | 2008 |
Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Neoplasms; Creatinine; Diphosphonates; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Male; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Risk Assessment; Treatment Outcome; Zoledronic Acid | 2008 |
[Prescription of bisphosphonates in prostate cancer].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Humans; Ibandronic Acid; Imidazoles; Injections; Male; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Zoledronic Acid | 2008 |
Clinical and radiologic response in patients with bone metastases managed with combined radiotherapy and bisphosphonates.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Osteogenesis; Pain Measurement; Pamidronate; Radiotherapy, Adjuvant; Zoledronic Acid | 2008 |
[Bisphosphonates for osseus invasion caused by bronchial carcinoma].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bronchial Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Osteoporosis; Zoledronic Acid | 2008 |
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Cancer Care Facilities; Creatinine; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Multivariate Analysis; Neoplasms; Proportional Hazards Models; Renal Insufficiency; Retrospective Studies; Zoledronic Acid | 2009 |
The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats.
Topics: Absorptiometry, Photon; Animals; Biomechanical Phenomena; Bone Density; Coated Materials, Biocompatible; Diphosphonates; Durapatite; Female; Ibandronic Acid; Imidazoles; Implants, Experimental; Microscopy, Electron, Scanning; Ovariectomy; Pamidronate; Rats; Rats, Sprague-Dawley; Surface Properties; Tibia; Titanium; X-Ray Microtomography; Zoledronic Acid | 2009 |
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Greece; Humans; Ibandronic Acid; Imidazoles; Incidence; Jaw Diseases; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2009 |
Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro.
Topics: Analysis of Variance; Apoptosis; Bone Density Conservation Agents; Cell Movement; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelial Cells; Endothelium, Vascular; Humans; Ibandronic Acid; Imidazoles; Leukocytes, Mononuclear; Neovascularization, Physiologic; Pamidronate; Statistics, Nonparametric; Stem Cells; Umbilical Veins; Zoledronic Acid | 2011 |
Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Health Care Costs; Health Resources; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Kidney; Kidney Function Tests; Middle Aged; Renal Insufficiency; State Medicine; Zoledronic Acid | 2010 |
An in vitro assay to measure targeted drug delivery to bone mineral.
Topics: Alendronate; Anabolic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Drug Delivery Systems; Durapatite; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Nuclear Magnetic Resonance, Biomolecular; Pamidronate; Risedronic Acid; Zoledronic Acid | 2010 |
Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Liver Cirrhosis, Biliary; Male; Middle Aged; Osteoporosis; Pamidronate; Retrospective Studies; Zoledronic Acid | 2011 |
Postmenopausal osteoporosis: another approach to management.
Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Medication Adherence; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Risk Assessment; Secondary Prevention; Zoledronic Acid | 2010 |
Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.
Topics: Apoptosis; Bone Density Conservation Agents; Cell Culture Techniques; Cell Movement; Cell Survival; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelial Cells; Endothelium, Vascular; Fibroblasts; Fluoresceins; Fluorescent Dyes; Humans; Ibandronic Acid; Imidazoles; In Situ Nick-End Labeling; Nitrogen; Osteoblasts; Pamidronate; Umbilical Veins; Zoledronic Acid | 2011 |
Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro.
Topics: Bone Density Conservation Agents; Cell Culture Techniques; Cell Line; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Ibandronic Acid; Imidazoles; Osteoblasts; Osteoprotegerin; RANK Ligand; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Zoledronic Acid | 2012 |
Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.
Topics: Bone Density Conservation Agents; Cell Line; Cell Movement; Cell Proliferation; Cell Shape; Cell Survival; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Ibandronic Acid; Imidazoles; Jaw Diseases; Mesenchymal Stem Cells; Osteonecrosis; Time Factors; Zoledronic Acid | 2010 |
Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Cell Culture Techniques; Cell Differentiation; Clodronic Acid; Core Binding Factor Alpha 1 Subunit; Diphosphonates; Dose-Response Relationship, Drug; Gene Expression Regulation; Homeodomain Proteins; Humans; Ibandronic Acid; Imidazoles; MSX1 Transcription Factor; Osteoblasts; Osteocalcin; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transcription Factors; Zoledronic Acid | 2011 |
Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Michigan; Middle Aged; Neoplasm Staging; Population Surveillance; Registries; Retrospective Studies; Risedronic Acid; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2010 |
The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.
Topics: Apoptosis; Bone Density Conservation Agents; Cell Culture Techniques; Cell Line; Cell Movement; Cell Proliferation; Cell Survival; Clodronic Acid; Coloring Agents; Diphosphonates; Fluoresceins; Fluorescent Dyes; Humans; Ibandronic Acid; Imidazoles; In Situ Nick-End Labeling; Keratinocytes; Mouth Mucosa; Pamidronate; Tetrazolium Salts; Thiazoles; Zoledronic Acid | 2012 |
Intravenous bisphosphonates for post-menopausal osteoporosis: adherence to a network guideline.
Topics: 25-Hydroxyvitamin D 2; Aged; Bone Density Conservation Agents; Calcifediol; Calcium; Consensus; Diphosphonates; Drug Resistance; Electronic Health Records; Evidence-Based Medicine; Female; Guideline Adherence; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Zoledronic Acid | 2011 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Mandibular Diseases; Maxillary Diseases; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2012 |
Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Maxillary Diseases; Maxillary Sinusitis; Oroantral Fistula; Pamidronate; Radiography, Panoramic; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2012 |
Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Logistic Models; Male; Medicare; Medication Adherence; Osteoporosis; Patient Compliance; United States; Zoledronic Acid | 2012 |
Osteopathology induced by bisphosphonates and dental implants: clinical observations.
Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Debridement; Dental Implants; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Male; Mandible; Mandibular Neoplasms; Maxilla; Neoplasms; Osteomyelitis; Osteoporosis; Pamidronate; Risk Factors; Time Factors; Zoledronic Acid | 2013 |
Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Topics: Acute-Phase Reaction; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Incidence; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Zoledronic Acid | 2013 |
Effects of bisphosphonates in combination with ionizing radiation and antioxidants on the growth of prostate and melanoma cells lines.
Topics: Animals; Antioxidants; Apigenin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Melanoma; Mice; Pamidronate; Prostatic Neoplasms; Radiation, Ionizing; Skin Neoplasms; Zoledronic Acid | 2013 |
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Managed Care Programs; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Teriparatide; United States; Zoledronic Acid | 2014 |
Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Incidence; Male; Markov Chains; Osteoporosis; Osteoporotic Fractures; Risk Factors; Sweden; Treatment Outcome; Zoledronic Acid | 2014 |
Which bisphosphonate to treat bone metastases?
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Zoledronic Acid | 2014 |
In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Chemotaxis; Clodronic Acid; Diphosphonates; Flow Cytometry; Granulocytes; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Neutrophils; Pamidronate; Phagocytosis; Respiratory Burst; Zoledronic Acid | 2015 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid | 2015 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Connexins; Diphosphonates; Etidronic Acid; Female; Hemiterpenes; Humans; Ibandronic Acid; Imidazoles; MCF-7 Cells; Multidrug Resistance-Associated Proteins; Nerve Tissue Proteins; Organophosphorus Compounds; Osteoclasts; Phosphate Transport Proteins; Probenecid; Risedronic Acid; Zoledronic Acid | 2014 |
The influence of geranylgeraniol on human oral keratinocytes after bisphosphonate treatment: An in vitro study.
Topics: Apoptosis; Bone Density Conservation Agents; Cell Culture Techniques; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Clodronic Acid; Diphosphonates; Diterpenes; Humans; Ibandronic Acid; Imidazoles; Keratinocytes; Mouth Mucosa; Pamidronate; Zoledronic Acid | 2015 |
Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Kidney; Nephrectomy; Rats; Rats, Wistar; Renal Insufficiency; Zoledronic Acid | 2015 |
Atypical femoral fracture following zoledronic acid treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Femoral Fractures; Fracture Fixation; Humans; Ibandronic Acid; Imidazoles; Magnetic Resonance Imaging; Osteoporosis; Treatment Outcome; Withholding Treatment; Zoledronic Acid | 2016 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2016 |
Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Databases, Factual; Denosumab; Diphosphonates; Drug Utilization; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Kaplan-Meier Estimate; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Teriparatide; United States; Zoledronic Acid | 2017 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Colitis, Ulcerative; Data Interpretation, Statistical; Diphosphonates; Female; Gastrointestinal Agents; Humans; Ibandronic Acid; Imidazoles; Intention to Treat Analysis; Male; Medication Adherence; Mesalamine; Models, Statistical; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Treatment Outcome; Zoledronic Acid | 2017 |
Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Topics: Acute-Phase Reaction; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Risk Factors; Severity of Illness Index; Zoledronic Acid | 2017 |
In Vitro Investigation of the Antimicrobial Effect of Three Bisphosphonates Against Different Bacterial Strains.
Topics: Anti-Infective Agents; Diphosphonates; Gram-Negative Bacteria; Gram-Positive Bacteria; Ibandronic Acid; Microbial Sensitivity Tests; Microbiota; Mouth; Pamidronate; Zoledronic Acid | 2018 |
Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro.
Topics: Administration, Oral; Alendronate; Apoptosis; Cell Movement; Cell Survival; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelial Cells; Fibroblasts; Humans; Ibandronic Acid; In Vitro Techniques; Infusions, Intravenous; Osteoblasts; Zoledronic Acid | 2018 |
Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee.
Topics: Aged; Arthralgia; Biomarkers; Bone Density Conservation Agents; Bone Marrow Diseases; Collagen Type I; Denosumab; Dietary Supplements; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Middle Aged; Peptide Fragments; Peptides; Procollagen; Retrospective Studies; Vitamin D; Zoledronic Acid | 2020 |
Impact of bisphosphonates on the proliferation and gene expression of human fibroblasts.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cell Differentiation; Cell Proliferation; Diphosphonates; Fibroblasts; Gene Expression Regulation; Humans; Ibandronic Acid; Jaw; Osteoblasts; Real-Time Polymerase Chain Reaction; Zoledronic Acid | 2019 |
Effects of Injected Antiosteoporotic Medication Versus Oral Bisphosphonates on Rates of Repeated Vertebroplasty or Kyphoplasty.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density Conservation Agents; Denosumab; Drug Therapy, Combination; Female; Fractures, Compression; Humans; Ibandronic Acid; Injections; Male; Middle Aged; Recurrence; Reoperation; Teriparatide; Vertebroplasty; Zoledronic Acid | 2020 |
Incidence of giant cell arteritis after bisphosphonate exposure: A retrospective cohort study.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Databases, Factual; Female; Giant Cell Arteritis; Humans; Ibandronic Acid; Incidence; Male; Medicare; Middle Aged; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; United States; Zoledronic Acid | 2021 |
Geranyl-geraniol addition affects potency of bisphosphonates-a comparison in vitro promising a therapeutic approach for bisphosphonate-associated osteonecrosis of the jaw and oral wound healing.
Topics: Acyclic Monoterpenes; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Endothelial Cells; Humans; Ibandronic Acid; Jaw Diseases; Mouth Diseases; Osteonecrosis; Wound Healing; Zoledronic Acid | 2022 |
Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; China; Cost-Benefit Analysis; Denosumab; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Teriparatide; Zoledronic Acid | 2021 |
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; United States; Zoledronic Acid | 2022 |
Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Male; Medication Adherence; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Taiwan; Teriparatide; Zoledronic Acid | 2022 |
Real-world effectiveness of osteoporosis treatments in Germany.
Topics: Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Fractures, Bone; Germany; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Zoledronic Acid | 2022 |
Bisphosphonate type-dependent cell viability suppressive effects of carbon nanohorn-calcium phosphate-bisphosphonate nanocomposites.
Topics: Animals; Bone Neoplasms; Bone Resorption; Calcium Phosphates; Carbon; Cell Survival; Diphosphonates; Drug Carriers; Ibandronic Acid; Mice; Nanocomposites; Osteoclasts; Pamidronate; Reactive Oxygen Species; Zoledronic Acid | 2022 |
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Registries; Spinal Fractures; Zoledronic Acid | 2023 |
Clinicians' views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid | 2023 |